| Literature DB >> 17521504 |
Abstract
beta-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on beta-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17521504 DOI： 10.1007/s11897-007-0009-2
Source DB: PubMed Journal: Curr Heart Fail Rep ISSN： 1546-9530